high5immunology.tv | IBD | ECCO 2023

Targeting efficacy: Discussions

ECCO 2023

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

JAK inhibitors - small molecules to treat IBD

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

S1P modulators - a rising class of drugs

ELEVATE, True North OLE

ECCO 2023

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

New molecules on the horizon!

APOLLO-CD, ARTEMIS-UC

ECCO 2023

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

A focus on surgery and post-operative maintenance

LIR!C, REPREVIO

Targeting efficacy ENG

ECCO 2023

Massimo Claudio Fantini, MD

Prolonged treatment with Ozanimod recaptures remission...

True North OLE

ECCO 2023

Séverine Vermeire, MD

Upadacitinib is efficacious for UC regardless of...

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Silvio Danese, MD

Long-term extension of ustekinumab in UC

UNIFI

ECCO 2023

Axel Dignaß, MD

Latest update on JAK inhibition

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

James Lindsay, MD

Vedolizumab heals pouch mucosa

EARNEST

ECCO 2023

Axel Dignaß, MD

S1P modulators in UC

True North, True North OLE, ELEVATE

ECCO 2023

James Lindsay, MD

Upadacitinib works in bionaive and bio-exposed pts in...

U-EXCEL, U-EXCEED, U-ENDURE U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Gerhard Rogler, MD

No impact of previous therapies for Upadacitinib in...

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

Fernando Magro, MD

Mucosal healing induced by vedolizumab in chronic...

EARNEST

ECCO 2023

Gerassimos Mantzaris, MD

Medium-term outcome of IBD patients diagnosed at...

ECCO 2023

Peter Irving, MD

Upadacitinib for fistulizing Crohn´s disease?

U-ENDURE, U-EXCEED, U-EXCEL

ECCO 2023

Séverine Vermeire, MD

Long-term duration of response with ozanimod in UC

True North OLE

Targeting efficacy Multi Language

ECCO 2023

Gerassimos Mantzaris, MD

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που...

ECCO 2023

Massimo Claudio Fantini, MD

Il prolungamento del trattamento con Ozanimod induce...

True North OLE

ECCO 2023

Séverine Vermeire, MD

Lang Termijn respons met ozanimod bij colitis ulcerosa

True North OLE

ECCO 2023

Séverine Vermeire, MD

Upadacitinib is efficient bij colitis ulcerosa,...

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Silvio Danese, MD

Studio lungo termine di ustekinumab in UC

UNIFI

ECCO 2023

Axel Dignaß, MD

Update zu JAK-Inhibitoren bei CED

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

Axel Dignaß, MD

S1P-Modulatoren bei Colitis ulcerosa

True North, True North OLE, ELEVATE

ECCO 2023

Gerhard Rogler, MD

Upadacitinib: Vortherapien spielen keine Rolle mehr bei...

U-EXCEL, U-EXCEED, U-ENDURE

Targeting safety: Discussions

ECCO 2023

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

Anti-IL23 drugs: is it all the same?

ADVANCE, MOTIVATE, FORTIFY, GETAID, LUCENT-1 & -2

ECCO 2023

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

New aspects on safety of anti-TNF treatment

GETAID

ECCO 2023

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

Safety update on JAKis - new worries?

U-ACHIEVE, U-ACCOMPLISH, FINCH

ECCO 2023

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

S1P-modulators: a spotlight on safety

True North OLE, ELEVATE

Targeting safety ENG

ECCO 2023

Massimo Claudio Fantini, MD

Etrasimod shows fast stool frequency and rectal...

ELEVATE

ECCO 2023

Gerhard Rogler, MD

Ileostomy with better prognosis than pouch in PSC

EpiPSC2

ECCO 2023

Gerassimos Mantzaris, MD

Positive effects of Upadacitinib on resolution of...

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Massimo Claudio Fantini, MD

Ozanimod shows good efficacy and safety profile in UC...

True North OLE

ECCO 2023

David Laharie, MD

Risk of IBD from early antibiotic exposure in live

Targeting safety Multi Language

ECCO 2023

Massimo Claudio Fantini, MD

Rapido controllo del sanguinamento rettale e della...

ELEVATE

ECCO 2023

Gerhard Rogler, MD

Ileostomie mit besserer Prognose als Pouch bei PSC

EpiPSC2

ECCO 2023

Gerassimos Mantzaris, MD

Το upadacitinib επιφέρει ύφεση των κοιλιακών...

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Massimo Claudio Fantini, MD

Ozanimod shows good efficacy and safety profile after...

True North OLE

ECCO 2023

David Laharie, MD

Les antibiotiques dans la petite enfance augmentent le...

Therapeutic concepts: Discussions

ECCO 2023

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

10 years of Tofacitinib – still more lessons to learn

ECCO 2023

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

Practice-changing data on surgery in CD and UC

REPREVIO, EpiPSC2

Therapeutic concepts ENG

ECCO 2023

Fernando Magro, MD

Postoperative recurrence in CD

REPREVIO

ECCO 2023

Alexander Moschen, MD

Epigenetic fingerprinting - a novel tool for precision...

EPIC-CD

ECCO 2023

James Lindsay, MD

DNA methylation predicts response to biologics in IBD

EPIC-CD

ECCO 2023

David Laharie, MD

Timing of surgery in Crohn's disease

ECCO 2023

David Laharie, MD

Vedolizumab for preventing postoperative reccurence of...

REPREVIO

ECCO 2023

Iris Dotan, MD

Another clue for the role of the microbiome in PSC?

EpiPSC2

ECCO 2023

Iris Dotan, MD

Biologics in CD – is earlier better?

epi-IIRN

ECCO 2023

Gerassimos Mantzaris, MD

Is it feasible to stop anti-TNF treatment in...

GETECCU (EXIT)

ECCO 2023

Peter Irving, MD

Enteral nutrition - food for thought!

epi-IIRN based

ECCO 2023

Piotr Eder, MD

Ileocaecal Crohn's disease - should we call the surgeon...

ECCO 2023

Peter Irving, MD

Early treatment with biologics in IBD

epi-IIRN based

ECCO 2023

Stefan Schreiber, MD

New drugs on the block!

ELEVATE, UNIFI

ECCO 2023

Séverine Vermeire, MD

Surgical and post-operative management in CD

ECCO 2023

Stefan Schreiber, MD

Post-surgical Crohn's disease

REPREVIO

ECCO 2023

Axel Dignaß, MD

Peri- and postoperative management of CD

REPREVIO

ECCO 2023

Matthieu Allez, MD

Surgery in CD - resetting or not?

REPREVIO, LIR!C

ECCO 2023

Silvio Danese, MD

Vedolizumab prevents postoperative recurrence in CD

REPREVIO

Therapeutic concepts Multi Language

ECCO 2023

Iris Dotan, MD

Biologics in CD - is earlier better?

epi-IIRN

ECCO 2023

Iris Dotan, MD

Another clue for the role of the microbiome in PSC?

EpiPSC2

ECCO 2023

Gerassimos Mantzaris, MD

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες...

GETECCU (EXIT)

ECCO 2023

Stefan Schreiber, MD

Neue Substanzen!

ELEVATE, UNIFI

ECCO 2023

Piotr Eder, MD

Postać ileocekalna choroby Crohna - czy chirurgia ma...

ECCO 2023

Stefan Schreiber, MD

Chirurgischer Verlauf nach Morbus Crohn

REPREVIO

ECCO 2023

Séverine Vermeire, MD

Aanpak van de (post)operatieve Crohn patient

ECCO 2023

Silvio Danese, MD

Vedolizumab previene la recidiva post operatoria nei...

REPREVIO

ECCO 2023

Stefan Schreiber, MD

Biosimilars

ECCO 2023

Matthieu Allez, MD

Résection chirurgicale au course de la maladie de...

REPREVIO, LIR!C

ECCO 2023

Axel Dignaß, MD

Peri- und postoperatives Management bei Morbus Crohn

REPREVIO

ECCO 2023

David Laharie, MD

Vedolizumab en prévention de la récidive postopératoire...

REPREVIO

ECCO 2023

Alexander Moschen, MD

Epigenetic Fingerprinting - ein neues Werkzeug für die...

EPIC-CD

ECCO 2023

David Laharie, MD

Résection chirurgicale précoce dans la MC

Treatment goals: Discussions

ECCO 2023

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

Comprehensive remission - the new standard!?

IBD-BOOST survey, LUCENT-1, LUCENT-2

ECCO 2023

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

Histology - a new therapeutic target in UC?

EARNEST

Treatment goals ENG

ECCO 2023

Fernando Magro, MD

Disease clearance induced by etrasimod in UC

ELEVATE

ECCO 2023

Stefan Schreiber, MD

Comprehensive Disease Control

Treatment goals Multi Language

ECCO 2023

Stefan Schreiber, MD

Comprehensive Disease Control

Varia ENG

ECCO 2023

Alexander Moschen, MD

GPX4 fueling postoperative recurrence in Crohn's...

ECCO 2023

Iris Dotan, MD

Mucosal signatures suggest a mechanism for early CD...

ECCO 2023

Fernando Gomollón, MD

Our patients will be better off in the near future!

ECCO 2023

Alessandro Armuzzi, MD

Sequencing in IBD - congress overview

ECCO 2023

Piotr Eder, MD

New ECCO guidelines on extraintestinal manifestations...

ECCO guideline

ECCO 2023

Alessandro Armuzzi, MD

Comprehensive overview of surgery in IBD

ECCO 2023

Massimo Claudio Fantini, MD

New opportunities from the application of artificial...

Varia Multi Language

ECCO 2023

Alexander Moschen, MD

GPX4 fördert postoperatives Morbus Crohn Rezidiv

ECCO 2023

Iris Dotan, MD

Mucosal signatures suggest a mechanism for early CD...

ECCO 2023

Fernando Gomollón, MD

Una vida mejor en el futuro inmediato para nuestros...

ECCO 2023

Alessandro Armuzzi, MD

Sequencing nelle malattie infiammatorie cronicale...

ECCO 2023

Piotr Eder, MD

Nowe wytyczne ECCO dotyczące manifestacji...

ECCO 2023

Alessandro Armuzzi, MD

Panoramica completa sulla chirurgia nelle malattie...

ECCO 2023

Massimo Claudio Fantini, MD

Nuove opportunità dall’applicazione dell’intelligenza...